217 related articles for article (PubMed ID: 15782619)
1. [Clinical study on development of nontuberculous mycobacterial lung disease].
Kurashima A
Kekkaku; 2004 Dec; 79(12):737-41. PubMed ID: 15782619
[TBL] [Abstract][Full Text] [Related]
2. [Strategies for Mycobacterium avium complex infection control in Japan: how do they improve the present situation?].
Ogawa K; Sano C
Kekkaku; 2013 Mar; 88(3):355-71. PubMed ID: 23672176
[TBL] [Abstract][Full Text] [Related]
3. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
[TBL] [Abstract][Full Text] [Related]
4. [Non-tuberculous mycobacteriosis. What has been coming out].
Kajiki A
Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
Mizutani S
Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of non-tuberculous pulmonary mycobacteriosis].
Sakatani M; Nakajima Y
Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
[TBL] [Abstract][Full Text] [Related]
7. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
[TBL] [Abstract][Full Text] [Related]
8. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
Kawahara S; Nagare H
Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease.
Fujita M; Kajiki A; Tao Y; Miyazaki M; Ouchi H; Harada E; Ikegame S; Matsumoto T; Uchino J; Watanabe K; Nakanishi Y
J Infect Chemother; 2012 Apr; 18(2):146-51. PubMed ID: 21927844
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and treatment of pulmonary nontuberculous mycobacteriosis].
Kurashima A
Kekkaku; 2002 Dec; 77(12):815-21. PubMed ID: 12607341
[TBL] [Abstract][Full Text] [Related]
11. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
[TBL] [Abstract][Full Text] [Related]
12. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
13. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
[TBL] [Abstract][Full Text] [Related]
14. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
[TBL] [Abstract][Full Text] [Related]
15. Difference in drug susceptibility distribution and clinical characteristics between
Wang W; Yang J; Wu X; Wan B; Wang H; Yu F; Guo Y
J Med Microbiol; 2021 May; 70(5):. PubMed ID: 33999797
[No Abstract] [Full Text] [Related]
16. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
17. A survey of clarithromycin monotherapy and long-term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims.
Iwao T; Kato G; Ito I; Aramaki E; Kuroda T
Pharmacoepidemiol Drug Saf; 2020 Apr; 29(4):427-432. PubMed ID: 31876044
[TBL] [Abstract][Full Text] [Related]
18. [Role of new quinolones in the treatment of mycobacteriosis].
Kekkaku; 2003 Sep; 78(9):601-4. PubMed ID: 14577348
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
[TBL] [Abstract][Full Text] [Related]
20. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
